F8 and F9 mutations in US haemophilia patients: Correlation with history of inhibitor and race/ethnicity

Haemophilia

Volumn 18, Issue 3, 2012, Pages 375-382

  Miller, C H ^a   Benson, J ^a   Ellingsen, D ^a   Driggers, J ^a   Payne, A ^a   Kelly, F M ^a   Soucie, J M ^a   Craig Hooper, W ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

F8 mutation; F9 mutation; Factor IX; Factor VIII; Haemophilia; Inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 INHIBITOR; BLOOD CLOTTING INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CAUCASIAN; CHILD; DISEASE ASSOCIATION; DISEASE SEVERITY; ETHNICITY; EXON; FRAMESHIFT MUTATION; GENE DELETION; GENE MUTATION; GENOTYPE; HAPLOTYPE; HEMOPHILIA A; HEMOPHILIA B; HISPANIC; HUMAN; INFANT; INTRON; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MULTIPLEX POLYMERASE CHAIN REACTION; NEGRO; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; ADULT; AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FACTOR IX; FACTOR VIII; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INFANT; INTRONS; MALE; MUTATION; UNITED STATES; YOUNG ADULT;

EID: 84860334450     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02700.x     Document Type: Article

References (35)

1. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factor VIII and IX. Haemophilia 2006; 12(Suppl 6): 15-22.
2. Boekhorst J, Lari GR, D'Oiron R et al. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia 2008; 14: 729-35.
3. Margaglione M, Castaman G, Morfini M et al. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica 2008; 93: 722-8.
4. Green PM, Bagnall RD, Waseem NH, Gianelli F. Haemophilia A mutations in the UK: results of screening one-third of the population. Br J Haematol 2008; 143: 115-28.
5. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1 beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
6. Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
7. Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-7.
8. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
9. D'Oiron R, Volot F, Reynaud J et al. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia A and inhibitors. Semin Hematol 2006; 43(1 Suppl 1): S3-9.
10. Ragni MV, Ojeifo O, Feng J et al. Risk factors for inhibitor development in haemophilia: a prevalent case-control study. Haemophilia 2009; 15: 1074-82.
11. Addiego J, Kasper C, Abildgaard C et al. Increased frequency of inhibitors in African American hemophilia A patients [abstract]. Blood 1994; 84(Suppl 1): 239.
12. Aledort LM, DiMichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
13. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.
14. Astermark J, Berntorp E, White GC, Kroner BL, MIBS Study Group. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development. Haemophilia 2001; 7: 267-72.
15. Viel KR, Ameri A, Abshire TC et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360: 1618-27.
16. CDC. Blood safety monitoring among persons with bleeding disorders - United States, May 1998-June 2002. MMWR 2003; 51: 1152-4.
17. Bagnall RD, Giannelli F, Green PM. Int22h-related inversions causing hemophilia A: a novel insight into their origin and a new more discriminant PCR test for their detection. J Thromb Haemost 2006; 4: 591-8.
18. Bagnall RD, Waseem N, Green PM, Gianelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood 2002; 99: 168-74.
19. Human Genome Variation Society. Available at Accessed January 3, 2011.
20. The Haemophilia A Mutation, Structure, Test, and Resource Site (HAMSTeRS). Available at Accessed January 3, 2011.
21. The Hemophilia B Mutation Database. Available at Accessed January 3, 2011.
22. Splice Site Prediction Program. Available at Accessed January 3, 2011.
23. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
24. Acquila M, Paino M, Lanza T, Bottini F, Molinari AC, Bicocchi MP. Duplication of exon 13 causes one-third of the cases of mild hemophilia in northern Italy. Haematologica 2004; 89: 758-9.
25. Knobe KE, Villoutreix BO, Tengborn LI, Petrini P, Ljung RC. Factor VIII inhibitors in two families with mild haemophilia A: structural analysis of the mutations. Haemostasis 2000; 30: 268-79.
26. Eckhardt CL, Menke LA, van Ommen CH et al. Intensive peri-operative use of factor VIII and the Arg593→Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009; 7: 930-7.
27. Kettering RP, Bottema CDK, Phillips JA, Sommers SS. Evidence that descendants of three founders constitute about 25% of the hemophilia B in the United States. Genomics 1991; 10: 1093-6.
28. CDC Hemophilia A Mutation Project (CHAMP) Mutation List. Available at Accessed July 29, 2011.
29. Gill JC. The role of genetics in inhibitor formation. Thromb Haemost 1999; 82: 500-4.
30. Tizzano EF, Cornet M, Domenech M, Baiget M. Modifier genes in haemophilia: their expansion in the human genome. Haemophilia 2002; 8: 250-4.
31. Rost S, Loffler S, Pavlova A, Muller CR, Oldenburg J. Detection of large duplications within the factor VIII gene by MLPA. J Thromb Haemost 2008; 6: 1996-9.
32. Thorland EC, Drost JB, Lusher JM et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999; 5: 101-5.
33. DiMichele D, Rivard G, Hay C, Antunes S. Inhibitors in haemophilia: clinical aspects. Haemophilia 2004; 10(Suppl 4): 140-5.
34. Aledort LM. Mild and moderate factor VIII deficiency: inhibitor risks. J Thromb Haemost 2009; 7: 928-9.
35. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. Am J Hemat 1998; 59: 288-94.